Briakinumab

Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.
Read more
€0.00 (tax incl.)
Reference:
HY-P99486
Product Details
HY-P99486

Data sheet

Size
Multiple sizes
Reactivity
Interleukin Related
Application
COVID-19-immunoregulation
CAS
339308-60-0

Menu

Settings